Diagnosis with associated treatment of peritoneal metastatic gastric cancer

doi:10.16139/j.1007-9610.2021.01.006

Abstract

CLC Number:

R735.2

ZHANG Jinghui, XU Yuan, YIN Kai. Diagnosis with associated treatment of peritoneal metastatic gastric cancer[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 28-33.

References 46

[1]	Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors[J]. Int J Cancer, 2014, 134(3):622-628. doi: 10.1002/ijc.28373 pmid: 23832847
[2]	Montori G, Coccolini F, Ceresoli M, et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art[J]. Int J Surg Oncol, 2014, 2014:912418.
[3]	Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition[J]. Gastric Cancer, 2011, 14(2):101-112.
[4]	Hasegawa H, Fujitani K, Nakazuru S, et al. Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom/tumor marker-based versus CT-based[J]. Anticancer Res, 2014, 34(9):5169-5174. pmid: 25202110
[5]	Arslan H, Fatih Ozbay M, Calli I, et al. Contribution of diffusion weighted MRI to diagnosis and staging in gastric tumors and comparison with multi-detector computed tomography[J]. Radiol Oncol, 2017, 51(1):23-29. doi: 10.1515/raon-2017-0002 pmid: 28265229
[6]	Ytre-Hauge S, Dybvik JA, Lundervold A, et al. Preoperative tumor texture analysis on MRI predicts high-risk di-sease and reduced survival in endometrial cancer[J]. J Magn Reson Imaging, 2018, 48(6):1637-1647. doi: 10.1002/jmri.26184 pmid: 30102441
[7]	Kim HY, Kim YH, Yun G, et al. Could texture features from preoperative CT image be used for predicting occult peritoneal carcinomatosis in patients with advanced gastric cancer?[J]. PLoS One, 2018, 13(3):e0194755.
[8]	Benson AB 3rd, Venook AP, Bekaii-Saab T, et al. Colon cancer, version 3.2014[J]. J Natl Compr Canc Netw, 2014, 12(7):1028-1059.
[9]	Li Z, Li Z, Jia S, et al. Depth of tumor invasion and tumor-occupied portions of stomach are predictive factors of intra-abdominal metastasis[J]. Chin J Cancer Res, 2017, 29(2):109-117.
[10]	Emoto S, Ishigami H, Yamashita H, et al. Clinical signifi-cance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination[J]. Gastric Cancer, 2012, 15(2):154-161.
[11]	Takata A, Kurokawa Y, Fujiwara Y, et al. Prognostic va-lue of CEA and CK20 mRNA in the peritoneal lavage fluid of patients undergoing curative surgery for gastric cancer[J]. World J Surg, 2014, 38(5):1107-1111.
[12]	Satoh Y, Mori K, Kitano K, et al. Analysis for the combination expression of CK20, FABP1 and MUC2 is sensitive for the prediction of peritoneal recurrence in gastric cancer[J]. Jpn J Clin Oncol, 2012, 42(2):148-152.
[13]	Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma[J]. Ann Surg, 2009, 250(2):242-246.
[14]	Lemoine L, Sugarbaker P, van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma[J]. Int J Hyperthermia, 2017, 33(5):582-592.
[15]	Ito S, Ohashi Y, Sasako M. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial[J]. BMC Cancer, 2018, 18(1):449.
[16]	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4)[J]. Gastric Cancer, 2017, 20(1):1-19.
[17]	Shirao K, Boku N, Yamada Y, et al. Randomized phase Ⅲ study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)[J]. Jpn J Clin Oncol, 2013, 43(10):972-980.
[18]	Nakayama I, Chin K, Matsushima T, et al. Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis[J]. Int J Clin Oncol, 2017, 22(6):1060-1068. doi: 10.1007/s10147-017-1164-4 pmid: 28748355
[19]	Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis[J]. Gastric Cancer, 2017, 20(Suppl 1):111-121. doi: 10.1007/s10120-016-0662-9 pmid: 27803990
[20]	van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer[J]. Lancet, 2016, 388(10060):2654-2664. doi: S0140-6736(16)30354-3 pmid: 27156933
[21]	Wilke H, Muro K, van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11):1224-1235.
[22]	Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance[J]. Int J Clin Oncol, 2015, 20(2):273-281.
[23]	Kelly RJ. Immunotherapy for esophageal and gastric cancer[J]. Am Soc Clin Oncol Educ Book, 2017, 37:292-300.
[24]	Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2016, 17(6):717-726. doi: S1470-2045(16)00175-3 pmid: 27157491
[25]	Ni X, Wu P, Wu J, et al. Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites[J]. Oncol Lett, 2017; 14(2):1691-1696.
[26]	Rau B, Brandl A, Piso P, et al. Peritoneal metastasis in gastric cancer: results from the German database[J]. Gastric Cancer, 2020, 23(1):11-22.
[27]	Li Y, Zhou YF, Liang H, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies[J]. World J Gastroenterol, 2016, 22(30):6906-6916.
[28]	Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 2011, 18(6):1575-1581.
[29]	Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis[J]. J Clin Oncol, 2019, 37(23):2028-2040.
[30]	Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases[J]. Int J Hyperthermia, 2017, 33(5):562-570.
[31]	Chan DY, Syn NL, Yap R, et al. Conversion surgery post-intraperitoneal paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. Are we ready?[J]. J Gastrointest Surg, 2017, 21(3):425-433.
[32]	Imano M, Peng YF, Itoh T, et al. A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis[J]. Anticancer Res, 2012, 32(9):4071-4075.
[33]	Yamaguchi H, Kitayama J, Ishigami H, et al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis[J]. Cancer, 2013, 119(18):3354-3358. doi: 10.1002/cncr.28204 pmid: 23798046
[34]	Ishigami H, Fujiwara Y, Fukushima R, et al. Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial[J]. J Clin Oncol, 2018, 36(19):1922-1929.
[35]	Alyami M, Hubner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7):e368-e377.
[36]	Giger-Pabst U, Demtroder C, Falkenstein TA, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma[J]. BMC Cancer, 2018, 18(1):442. doi: 10.1186/s12885-018-4363-0 pmid: 29669524
[37]	Alyami M, Bonnot PE, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for nonresectable peritoneal metastasis from gastric cancer[J]. Eur J Surg Oncol, 2019, 45:592.
[38]	Wu P, Wang P, Ma B, et al. Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis[J]. Cancer Manag Res, 2018, 10:4759-4771.
[39]	朱正纲. 晚期胃癌转化治疗的理念与临床意义[J]. 外科理论与实践, 2017, 22(1):1-4.
[40]	Okabe H, Ueda S, Obama K, et al. Induction chemothe-rapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination[J]. Ann Surg Oncol, 2009, 16(12):3227-3236.
[41]	Ramos M, Pereira MA, Charruf AZ, et al. Conversion therapy for gastric cancer: expanding the treatment possibilities[J]. Arq Bras Cir Dig, 2019, 32(2):e1435.
[42]	Koemans WJ, van der Kaaij RT, Boot H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE Ⅱ)[J]. BMC Cancer, 2019, 19(1):420. doi: 10.1186/s12885-019-5640-2 pmid: 31060544
[43]	Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage Ⅳ gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2):329-338.
[44]	Ishigami H, Yamaguchi H, Yamashita H, et al. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings[J]. Gastric Cancer, 2017, 20(Suppl 1):128-134.
[45]	Cho H, Ryu MH, Kim KP, et al. Phase Ⅰ/Ⅱ study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis[J]. Gastric Cancer, 2017, 20(6):970-977.
[46]	Fushida S, Kinoshita J, Yagi Y, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study[J]. Oncol Rep, 2008, 19(5):1305-1310. pmid: 18425392

Diagnosis with associated treatment of peritoneal metastatic gastric cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 46

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YAN Chao, LU Sheng, YAN Min, ZHU Zhenggang. Chinese interpretation of Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) and Ruijin clinical practice [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 326-354.
[2]	SUN Qi, HUANG Wenbo, HE Bingliang, LIU Chang, XU Yuhang, ZHAO Wei. Efficacy with prognostic value of postoperative prophylactic hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 366-370.
[3]	SUN Qiang, YAO Jun, ZHANG Xin, DU Shanshan, WANG Weijun. Research progress of anti reflux digestive tract reconstruction for proximal gastrectomy [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 388-393.
[4]	YAN Su, ZHENG Minhua. Practice of single-port and reduced-port laparoscopic gastric cancer surgery in China [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 233-239.
[5]	HU Wenqing, YANG Yinhao, CUI Peng, WEI Wei. Current status of high-positioned digestive tract reconstruction after laparoscopic proximal stomach and lower esophagus resection through the abdominal-left diaphragmatic approach for adenocarcinoma of esophagogastric junction [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 226-232.
[6]	FAN Qingquan, SONG Xiaoling, GU Jun. Exosome in gastric cancer: research and perspective [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 177-180.
[7]	DENG Shijie, YUAN Fei. Advances in diagnosis and molecular detection of EBV-positive gastric cancer and gastric cancer with lymphoid stroma [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 53-57.
[8]	ZHANG Huan, CHEN Yong. New progression of radiomics in diagnosis of gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 42-48.
[9]	LIU Wentao, LIU Fukun. Summary and prospect of perioperative comprehensive treatment for gastric cancer in China [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 36-41.
[10]	LI Guoli, GUO Feilong. Preoperative chemotherapy through intra-arterial combined with intra-venous administration in treatment of advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 31-35.
[11]	ZHAO Fazhi, ZHAO Ping. Formation and improvement of surgery-based treatment system for gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 24-30.
[12]	LU Yiming, XIONG Jianping, TIAN Yantao. Current status and prospect of conversion therapy for far-advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 17-23.
[13]	LI Jianfang, YU Junxian, YAN Chao, ZHU Zhenggang, LIU Bingya. Hotspots in basic and translational research of gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 7-16.
[14]	ZHU Zhenggang. Progress and prospect of surgical comprehensive treatment of gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 1-6.
[15]	LUO Xi, SHI Yongmei, CHEN Ke, JIANG Shuo, WU Yuwei. Analysis on evaluation of patients with gastric and colon cancer using modified patient-generated subjective global assessment [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 545-550.